SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version Revision Date SDS Number: Date of last issue: 2021
2.1 27.08.2021 7602788-00004 11.03.2021
11.03.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Milbemycin Oxime / Lufenuron / Praziquantel Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
Company : MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Skin sensitisation, Category 1 : H317: May cause an allergic skin reaction.
Reproductive toxicity, Category 1B : H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1 : H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1 : H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Danger

Hazard statements :
H317 May cause an allergic skin reaction.
H360D May damage the unborn child.
H373 May cause damage to organs through prolonged or
repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements:

Prevention:
P201 Obtain special instructions before use.
P273 Avoid release to the environment.
P280 Wear protective gloves/protective clothing/eye protection/face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:
lufenuron (ISO)

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>lufenuron (ISO)</td>
<td>103055-07-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>410-690-9</td>
<td>Skin Sens. 1; H317 Repr. 1B; H360D STOT RE 1; H372 (Central nervous system, Lungs, Liver, Stomach)</td>
<td>&gt;= 2.5 - &lt; 10</td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical...
Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause an allergic skin reaction. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-: Exposure to combustion products may be a hazard to health.
fighting

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Metal oxides
Chlorine compounds

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.
SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapours or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

7.3 Specific end use(s)

Specific use(s): No data available
## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>lufenuron (ISO)</td>
<td>103055-07-8</td>
<td>TWA</td>
<td>OEB 3 (&gt;= 10 &lt; 100 µg/m³)</td>
<td>Internal</td>
</tr>
<tr>
<td>Savorysel Bacon Flavor</td>
<td>Not Assigned</td>
<td>Wipe limit</td>
<td>OEB 2 (&gt;= 100 &lt; 1000 µg/m³)</td>
<td>Internal</td>
</tr>
<tr>
<td>praziquantel</td>
<td>55268-74-1</td>
<td>TWA</td>
<td>0.5 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Milbemycin Oxime</td>
<td>129496-10-2</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>443.28 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>443.28 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kg bw/day</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kg bw/day</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Ingestion</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
<td></td>
</tr>
<tr>
<td>Glycerine</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>56 mg/m³</td>
</tr>
<tr>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>229 mg/kg bw/day</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>33 mg/m³</td>
<td></td>
</tr>
</tbody>
</table>

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compart</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>lufenuron (ISO)</td>
<td>Water</td>
<td>0.2 µg/l</td>
</tr>
<tr>
<td>praziquantel</td>
<td>Fresh water</td>
<td>0.3 mg/l</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Fresh water</td>
<td>5 mg/l</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Skin and body protection

Material: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Remarks: Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

Filter type: Combined particulates and organic vapour type (A-P)

SECTON 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: solid
Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Colour : brown
Odour : characteristic
Odour Threshold : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Flash point : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
pH : No data available
Viscosity
Viscosity, kinematic : Not applicable
Solubility(ies)
Water solubility : soluble
Partition coefficient: n-octanol/water : Not applicable
Vapour pressure : Not applicable
Relative density : No data available
Density : No data available
Relative vapour density : Not applicable
Particle characteristics
Particle size : No data available

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : Not applicable
SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>27.08.2021</td>
<td>7602788-00004</td>
<td>11.03.2021</td>
<td>20.11.2020</td>
</tr>
</tbody>
</table>

Molecular weight: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Lufenuron (ISO):
Acute oral toxicity: LD50 (Rat): > 2.000 mg/kg
LD50 (Mouse): > 2.000 mg/kg

Acute inhalation toxicity: LC50 (Rat): 2.350 mg/m3
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2.000 mg/kg
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version 2.1 Revision Date: 27.08.2021 SDS Number: 7602788-00004 Date of last issue: 11.03.2021
Date of first issue: 20.11.2020

Savorysel Bacon Flavor:
Acute oral toxicity : Remarks: Based on available data, the classification criteria are not met.
Acute inhalation toxicity: Remarks: Not classified due to lack of data.
Acute dermal toxicity: Remarks: Based on available data, the classification criteria are not met.

praziquantel:
Acute oral toxicity: LD50 (Rat): 2.480 mg/kg
LD50 (Mouse): 2.454 mg/kg
LD50 (Dog): > 200 mg/kg
LD50 (Rabbit): 1.050 mg/kg

Milbemycin Oxime:
Acute oral toxicity: LD50 (Rat): 532 - 863 mg/kg
LD50 (Mouse): 722 - 946 mg/kg
Acute toxicity estimate: 532 mg/kg
Method: Calculation method

Acute inhalation toxicity: LC50 (Rat): 1.200 mg/m³
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity estimate: 1.2 mg/l
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity: LD50 (Rat): > 2.000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
lufenuron (ISO):
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Savorysel Bacon Flavor:
Remarks: Based on data from similar materials
May irritate skin.
praziquantel:
Species: Rabbit
Method: Draize Test
Remarks: slight irritation

Milbemycin Oxime:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Lufenuron (ISO):
Species: Rabbit
Method: Draize Test
Result: No eye irritation

Savorysel Bacon Flavor:
Remarks: Based on data from similar materials
May irritate eyes.

praziquantel:
Species: Rabbit
Method: Draize Test
Result: Mild eye irritation

Milbemycin Oxime:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
May cause an allergic skin reaction.

Respiratory sensitisation
Not classified based on available information.

Components:

Lufenuron (ISO):
Test Type: Maximisation Test
Species: Guinea pig
Assessment: May cause sensitisation by skin contact.
Result: Sensitiser
**SAFETY DATA SHEET**

according to Regulation (EC) No. 1907/2006

### Milbemycin Oxime / Lufenuron / Praziquantel

**Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>27.08.2021</td>
<td>7602788-00004</td>
<td>11.03.2021</td>
<td>20.11.2020</td>
</tr>
</tbody>
</table>

#### Savorysel Bacon Flavor:

**Remarks:** Not classified due to lack of data.

#### praziquantel:

**Test Type:** Maximisation Test  
**Exposure routes:** Dermal  
**Species:** Guinea pig  
**Result:** Not a skin sensitizer.

**Germ cell mutagenicity**  
Not classified based on available information.

**Components:**

#### lufenuron (ISO):

**Genotoxicity in vitro**  
- **Test Type:** Ames test  
  - Result: negative

  - **Test Type:** Mouse Lymphoma  
    - Test system: Chinese hamster cells  
    - Result: negative

  - **Test Type:** Cytogenetic assay  
    - Test system: Chinese hamster ovary cells  
    - Result: negative

  - **Test Type:** DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
    - Test system: rat hepatocytes  
    - Result: negative

  - **Test system:** Human lymphocytes  
    - Result: negative

**Genotoxicity in vivo**  
- **Test Type:** Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
  - Species: Mouse  
  - Result: negative

  - **Test Type:** Unscheduled DNA synthesis test (UDS) in testicular cells  
    - Species: Rat  
    - Result: negative

**Germ cell mutagenicity- Assessment**  
Weight of evidence does not support classification as a germ cell mutagen.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version: 2.1
Revision Date: 27.08.2021
SDS Number: 7602788-00004
Date of last issue: 11.03.2021
Date of first issue: 20.11.2020

Savourysel Bacon Flavor:
Genotoxicity in vitro: Remarks: Not classified due to lack of data.
Genotoxicity in vivo: Remarks: Not classified due to lack of data.

praziquantel:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosomal aberration
Test system: Chinese hamster cells
Result: negative
Genotoxicity in vivo: Test Type: Micronucleus test
Species: Rat
Result: negative

Milbemycin Oxime:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosome aberration test in vitro
Result: negative
Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Lufenuron (ISO):
Species: Rat
Application Route: Ingestion
Exposure time: 18 month(s)
Result: negative
Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

praziquantel:
Species: Hamster
Application Route: Oral
Exposure time: 80 weeks
NOAEL: 100 mg/kg body weight
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>27.08.2021</td>
<td>7602788-00004</td>
<td>11.03.2021</td>
<td>20.11.2020</td>
</tr>
</tbody>
</table>

Result : negative
Remarks : No significant adverse effects were reported

Species : Rat
Application Route : Oral
Exposure time : 104 weeks
NOAEL : 250 mg/kg body weight
Result : negative
Remarks : No significant adverse effects were reported

Reproductive toxicity
May damage the unborn child.

Components:

**lufenuron (ISO):**

Effects on fertility :
Species: Rat
Application Route: Oral
General Toxicity - Parent: NOAEL: 8,3 mg/kg wet weight
Early Embryonic Development: NOAEL: 20,9 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development :
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: 500 mg/kg body weight
Developmental Toxicity: NOAEL: 1.000 mg/kg body weight
Symptoms: No adverse effects
Remarks: No significant adverse effects were reported

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: NOAEL: 20,9 mg/kg body weight
Embryo-foetal toxicity: 8,3 mg/kg body weight
Result: foetal abnormalities

Reproductive toxicity - Assessment
Clear evidence of adverse effects on development, based on animal experiments.

**Savorysel Bacon Flavor:**

Effects on fertility :
Remarks: No data available

Effects on foetal development :
Remarks: No data available

**praziquantel:**

Effects on fertility :
Test Type: Fertility
Species: Rat
Remarks: No significant adverse effects were reported
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version 2.1
Revision Date: 27.08.2021
SDS Number: 7602788-00004
Date of last issue: 11.03.2021
Date of first issue: 20.11.2020

Test Type: Fertility
Species: Mouse
Remarks: No significant adverse effects were reported

Effects on foetal development:

Test Type: Development
Species: Rat
Remarks: No significant adverse effects were reported

Test Type: Development
Species: Mouse
Remarks: No significant adverse effects were reported

STOT - single exposure
Not classified based on available information.

Components:

Lufenuron (ISO):
Assessment: The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Lufenuron (ISO):
Exposure routes: Oral
Target Organs: Central nervous system, Lungs, Liver, Stomach
Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.</th>
</tr>
</thead>
</table>

**Milbemycin Oxime:**
- **Exposure routes**: Ingestion
- **Target Organs**: Central nervous system
- **Assessment**: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity**

**Components:**

**Lufenuron (ISO):**
- **Species**: Rat
- **NOAEL**: 5.34 mg/kg
- **Application Route**: oral (feed)
- **Exposure time**: 4 Months
- **Target Organs**: Central nervous system, digestive system
- **Symptoms**: central nervous system effects

- **Species**: Rat
- **NOAEL**: 1.93 mg/kg
- **Application Route**: oral (feed)
- **Exposure time**: 2 yr
- **Symptoms**: central nervous system effects, Convulsions

- **Species**: Mouse
- **NOAEL**: 2.12 mg/kg
- **Application Route**: oral (feed)
- **Exposure time**: 18 Months
- **Target Organs**: Central nervous system, Liver, Prostate
- **Symptoms**: central nervous system effects, Convulsions

- **Species**: Dog
- **NOAEL**: 7.02 mg/kg
- **Application Route**: oral (feed)
- **Exposure time**: 1 yr
- **Target Organs**: Convulsions, Fatality, Irregularities

**Savorysel Bacon Flavor:**
- **Remarks**: Not classified due to lack of data.

**Praziquantel:**
- **Species**: Rat
- **NOAEL**: 1.000 mg/kg
- **Application Route**: Oral
- **Remarks**: No significant adverse effects were reported
Species: Dog
NOAEL: 60 mg/kg
LOAEL: 180 mg/kg
Application Route: Oral
Target Organs: Gastrointestinal tract
Remarks: No significant adverse effects were reported

Milbemycin Oxime:
Species: Rat
NOAEL: 3 mg/kg
LOAEL: 15 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Symptoms: Liver disorders, Blood disorders

Species: Dog
NOAEL: 8,6 mg/kg
LOAEL: Ingestion
Exposure time: 3 Days
Symptoms: Tremors

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards
Endocrine disrupting properties
Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure
Components:
lufenuron (ISO):
General Information: Remarks: May be harmful if swallowed.
                        May cause neurotoxic effects.

Savoryseal Bacon Flavor:
General Information: Remarks: Based on data from similar materials
                        May irritate skin.
                        May irritate eyes.

praziquantel:
Inhalation: Symptoms: Headache, Tiredness, Dizziness, Gastrointestinal discomfort, decrease body temperature, Allergic reactions
Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version 2.1  Revision Date: 27.08.2021  SDS Number: 7602788-00004  Date of last issue: 11.03.2021  Date of first issue: 20.11.2020

Milbemycin Oxime:
Ingestion: Symptoms: Salivation, Convulsions, Diarrhoea, Weakness, Vomiting, Tremors, Coma
Remarks: Based on Animal Evidence

Further information
Components:
Savorysel Bacon Flavor:
Remarks: No toxicology information is available.

SECTION 12: Ecological information

12.1 Toxicity
Components:
Lufenuron (ISO):
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 73.100 µg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): > 29.000 µg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 370 µg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Americamysis): 0,042 µg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants: EC50 (Raphidocelis subcapitata (freshwater green alga)): 209 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Scenedesmus subspicatus): 17 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 10.000

Toxicity to fish (Chronic toxicity): NOEC: 80 µg/l
Exposure time: 33 d
Species: Oncorhynchus mykiss (rainbow trout)
Method: OECD Test Guideline 210
**SAFETY DATA SHEET**
according to Regulation (EC) No. 1907/2006

**Milbemycin Oxime / Lufenuron / Praziquantel**
**Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>27.08.2021</td>
<td>7602788-00004</td>
<td>11.03.2021</td>
<td>20.11.2020</td>
</tr>
</tbody>
</table>

NOEC: 20 µg/l  
Exposure time: 359 d  
Species: Oncorhynchus mykiss (rainbow trout)  
Method: OECD Test Guideline 229

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**

| NOEC: 8.38 µg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211 |
|------------------|------------------|
| NOEC: 90 µg/l    
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211 |
| NOEC: 2 µg/l     
Exposure time: 21 d  
Species: Chironomus riparius (harlequin fly)  
Method: OECD Test Guideline 211 |

M-Factor (Chronic aquatic toxicity): 10

**praziquantel:**

**Toxicity to fish**:  
LC50 (Carassius auratus (goldfish)): 29.2 mg/l  
Exposure time: 96 hrs  
Method: OECD Test Guideline 203  

LC50 (Danio rerio (zebra fish)): 31.6 mg/l  
Exposure time: 96 hrs  
Method: OECD Test Guideline 203

**Toxicity to daphnia and other aquatic invertebrates**:  
EC50 (Daphnia magna (Water flea)): 35 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

**Toxicity to microorganisms**:  
EC50 (activated sludge): > 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition of activated sludge  
Method: OECD Test Guideline 209

**Milbemycin Oxime:**

**Toxicity to fish**:  
LC50 (Oncorhynchus mykiss (rainbow trout)): 0,16 µg/l  
Exposure time: 96 h

**Toxicity to daphnia and other aquatic invertebrates**:  
EC50 (Daphnia magna (Water flea)): 0,03 µg/l  
Exposure time: 48 h

**Toxicity to algae/aquatic plants**:  
EC50: > 87 µg/l  
Exposure time: 72 h

M-Factor (Acute aquatic toxicity): 10.000
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

- NOEC: 0.01 µg/l
- Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic toxicity): 10,000

### 12.2 Persistence and degradability

No data available

### 12.3 Bioaccumulative potential

**Components:**

**lufenuron (ISO):**
- Bioaccumulation
- Species: Lepomis macrochirus (Bluegill sunfish)
- Bioconcentration factor (BCF): 28
- Method: OECD Test Guideline 305
- Partition coefficient: n-octanol/water: log Pow: 5.12

**praziquantel:**
- Partition coefficient: n-octanol/water: log Pow: 2.012
  - pH: 7

**Milbemycin Oxime:**
- Bioaccumulation: Bioconcentration factor (BCF): 440
- Partition coefficient: n-octanol/water: log Pow: 7

### 12.4 Mobility in soil

**Components:**

**lufenuron (ISO):**
- Distribution among environmental compartments: log Koc: 5.38
- Method: OECD Test Guideline 106

### 12.5 Results of PBT and vPvB assessment

**Product:**
- Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

**Product:**
- Assessment: The substance/mixture does not contain components consid-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version 2.1 Revision Date: 27.08.2021 SDS Number: 7602788-00004 Date of last issue: 11.03.2021 Date of first issue: 20.11.2020

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th>ADN</th>
<th>UN 3077</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>UN 3077</td>
</tr>
<tr>
<td>RID</td>
<td>UN 3077</td>
</tr>
<tr>
<td>IMDG</td>
<td>UN 3077</td>
</tr>
<tr>
<td>IATA</td>
<td>UN 3077</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>ADN</th>
<th>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Milbemycin Oxime, lufenuron (ISO))</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Milbemycin Oxime, lufenuron (ISO))</td>
</tr>
<tr>
<td>RID</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Milbemycin Oxime, lufenuron (ISO))</td>
</tr>
<tr>
<td>IMDG</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Milbemycin Oxime, lufenuron (ISO))</td>
</tr>
<tr>
<td>IATA</td>
<td>Environmentally hazardous substance, solid, n.o.s. (Milbemycin Oxime, lufenuron (ISO))</td>
</tr>
</tbody>
</table>
14.3 Transport hazard class(es)

- ADN : 9
- ADR : 9
- RID : 9
- IMDG : 9
- IATA : 9

14.4 Packing group

- ADN
  - Packing group : III
  - Classification Code : M7
  - Hazard Identification Number : 90
  - Labels : 9
- ADR
  - Packing group : III
  - Classification Code : M7
  - Hazard Identification Number : 90
  - Labels : 9
  - Tunnel restriction code : (-)
- RID
  - Packing group : III
  - Classification Code : M7
  - Hazard Identification Number : 90
  - Labels : 9
- IMDG
  - Packing group : III
  - Labels : 9
  - EmS Code : F-A, S-F
- IATA (Cargo)
  - Packing instruction (cargo aircraft) : 956
  - Packing instruction (LQ) : Y956
  - Packing group : III
  - Labels : Miscellaneous
- IATA (Passenger)
  - Packing instruction (passenger aircraft) : 956
  - Packing instruction (LQ) : Y956
  - Packing group : III
  - Labels : Miscellaneous

14.5 Environmental hazards

- ADN
  - Environmentally hazardous : yes
- ADR
  - Environmentally hazardous : yes
SAFETY DATA SHEET
generated according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version 2.1 Revision Date: 27.08.2021 SDS Number: 7602788-00004 Date of last issue: 11.03.2021
Date of first issue: 20.11.2020

RID
Environmentally hazardous: yes

IMDG
Marine pollutant: yes

IATA (Passenger)
Environmentally hazardous: yes

IATA (Cargo)
Environmentally hazardous: yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable


<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS: not determined
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version 2.1  Revision Date: 27.08.2021  SDS Number: 7602788-00004  Date of last issue: 11.03.2021
Date of first issue: 20.11.2020

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H317 : May cause an allergic skin reaction.
H332 : Harmful if inhaled.
H360D : May damage the unborn child.
H372 : Causes damage to organs through prolonged or repeated exposure.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.
H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Repr. : Reproductive toxicity
Skin Sens. : Skin sensitisation
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Milbemycin Oxime / Lufenuron / Praziquantel
Formulation

Version 2.1  Revision Date: 27.08.2021  SDS Number: 7602788-00004  Date of last issue: 11.03.2021
Date of first issue: 20.11.2020

test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture:

<table>
<thead>
<tr>
<th>Category</th>
<th>Classification</th>
<th>Classification procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin Sens. 1</td>
<td>H317</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Repr. 1B</td>
<td>H360D</td>
<td>Calculation method</td>
</tr>
<tr>
<td>STOT RE 2</td>
<td>H373</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Acute 1</td>
<td>H400</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Chronic 1</td>
<td>H410</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN